Abstract: This system is characterized in that includes: means (20) for acquiring information relating to the respiratory state of the patient (1) over a breathing cycle, means (21) for acquiring information relating to the operating state of the assistance device (2) over a mechanical cycle, means for filtering (22) and for processing (23) this information in order to detect and localize the changes in states of the patient over a breathing cycle and of the device over a mechanical cycle, means (24) for calculating a piece of information on desynchronization between the patient and the device from these changes in states, and means (25) forming a man/machine interface for returning this piece of desynchronization information to an operator.

Abstract: The endovascular prosthesis includes a first expandable framework and a first jacket for the first framework, the first framework and the first jacket forming a first channel when the first framework is in the expanded state. The first framework and the first jacket each have at least one opening, which openings are arranged substantially opposite one another and through which a sleeve is received, the sleeve having a first end and a second end, the perimeter of the first end being attached to the perimeter of the opening of the first jacket, while the second end extends inside the first channel.

Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mineralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.

Abstract: The present invention relates to a method for measuring the activity of calcineurin in a biological sample wherein a kinase inhibitor is present in the assay reaction mix.

Abstract: The invention relates to the use of biotin for treating X-linked adrenoleukodistrophy, in particular adrenomyeloneuropathy.

Abstract: The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.

Abstract: The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms.

Abstract: The present invention relates to methods and compositions for stimulating reepithelialization during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialization of the skin or of the cornea during wound healing.

Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.

Abstract: The invention relates to a method for determining the activity of an autoinflammatory disease in a patient, where a patient reports the status of at least 5 dichotomous items corresponding to a physiological observation and the values of each status is combined in a mathematical function to obtain an end value.

Abstract: The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.

Abstract: The present invention relates to a soluble peptide comprising the amino acids sequence: KRFYVVMWKK (SEQ ID NO: 1) or a function-conservative variant thereof for use in the treatment of cancer. The invention also relates to a pharmaceutical composition for use in the treatment of cancer comprising at least one soluble peptide according to the invention or at least one acid nucleic according to the invention or at least one expression vector according to the invention, or at least one host cell according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which: the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined; it is deduced therefrom whether the individual is suffering from a neurodegenerative disease.

Abstract: The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising: i) determining the microRNA expression levels in a test cell expressing a receptor, a first co-receptor and at least one other co-receptor, after infection by a first virus using the first co-receptor and by at least one other virus using another co-receptor, respectively; ii) identifying the microRNAs, the expression level of which is modulated during the infection by each of the viruses in relation to the expression level in the uninfected cells; iii) comparing the thus-identified microRNAs; iv) selecting the microRNAs, the modification of the expression level of which is specific to the use of a co-receptor; v) optionally identifying the target mR

Abstract: The present invention concerns a polypeptide comprising the N-terminal fragment of a cystatin, and/or a cystatin expression inducer for use for the treatment of sterility and/or infertility, and a method of diagnosing and/or predicting sterility and/or infertility of a subject and/or of a couple of subjects, which method comprises measuring the level of at least one cystatin in a biological sample of a male subject and/or measuring the level of at least one cystatin in a biological sample of a female subject, and optionally measuring further the level of at least one cathepsin in a biological sample of said male of female subject.

Abstract: The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(?) iNKT cell sub-population. In particular, CD3+CD4? TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed.

Abstract: The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as ?-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free ?-Hb pool in a biological sample obtained from said subject.

Abstract: The present invention relates to interfering RNAs, in particular miRNAs, capable of specifically blocking the replication of a strain of the HIV virus that is resistant to an antiretroviral compound, and use thereof for treating infections by this type of virus.

Abstract: A process for calculating an indice of arterial stiffness, including the step of extracting pulse wave analysis data from a recorded pressure of an artery, the recorded pressure is recorded as a function of time, the indice being calculated as a function of the extracted data, and the extracted pulse wave analysis data including at least one time interval.

Abstract: The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient.